•	73
4	4

Form PTO-1449

INFORMATION DISCLOSURE CITATION **BY APPLICANT**

(Use several sheets if necessary)

	Sheet <u>1</u> of <u>1</u>
DOCKET NUMBER	US APPLICATION NUMBER
100507 - 1	10/051,776
APPLICANT	*
AstraZeneca AB	`
FILING DATE	GROUP ART UNIT
January 16, 2002	1614

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate	
		EODEICI	M DATENIT DOCUMENTO		1		

FOREIGN PATENT DOCUMENTS

	Document Number	Public Date	Public Date Country	Class	Subclass	<u>Translation</u>	
[İ	,			Yes	No	
					A .		
					\ \ \\)_	
					AUG		
	1			1 10%	~~ <u></u>	1/2	
	·			1 2	·		
	1			S	// d		
	T	· · · · · · · · · · · · · · · · · · ·			CR 100/200	05	
					1/0		
	1				1000		
					-70	,	
					' 9	9	
	1	l l					
	1						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

,	Gaster, et al., "The Selective 5-HT _{1B} Receptor Inverse Agonist 1'-Methyl-5-[[2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]carbonyl]-2,3,6,7-tetrahydrospiro[furo[2,3-f]indole-3,4'-piperidine] (SB-224289) Potently Blocks Terminal 5-HT Autoreceptor Function Both in Vitro and in Vivo" <i>J. Med. Chem.</i> , 41, 1218-1235 (1998)		
1	Russell, et al., "3-[3-(Piperidin-1-yl)propyl]indoles as Highly Selective h5-HT _{1D} Receptor Agonists", <i>J. Med. Chem.</i> , 42, 4981-5001, (1999)		
/	Barnes, et al., "A review of central 5-HT receptors and their function", <i>Neuropharmacology</i> 38, 1083-1152, (1999)		
/	Massot, et al., "5-HT1B Receptors: A Novel Target for Lithium", <i>Neuropsychopharmacology</i> Vol. 21, No. 4, 530-541		
7	Halazy, et al., "5-HT _{1B/1D} antagonists and depression", Exp. Opin. Ther. Patents, 7(4) 339352 (1997)		
/	Cryan et al., "5-HT _{1A} and Beyond: The Role of Serotonin and its Receptors in Depression and the Antidepressant Response", <i>Hum. Psychopharmacol. Clin. Exp.</i> , 15, 113-135 (2000)		
EXAMINE	DATÉ CONSIDERED		

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if not

in conformance and not considered. Include copy of this form with next communication to applicant.

PTO/SB/08 (2-92)

Patent and Trademark Of Patent and Trademark Office, U.S. Department of Commerce